JAK inhibitors in systemic lupus erythematosus: Translating pathogenesis into therapy. (PubMed, Lupus) - Oct 9, 2024 - "The efforts of the drug development programme in lupus have led to considerable growth in the last decade, owing to the approval of belimumab, anifrolumab, and voclosporin...Multiple JAKis are currently being investigated in SLE. This paper aims to summarize existing data coming from both clinical trials and case reports regarding the use of JAK inhibitors in SLE."
Journal • Review • Dermatology • Gastroenterology • Hematological Disorders • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Rheumatology • Systemic Lupus Erythematosus
|
|
Christopher J Edwards; Gabriela Ceobanu
|